Dr. Warnock is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1720 2nd Ave S
Birmingham, AL 35294- Is this information wrong?
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1971 - 1973- University of California (San Francisco)Internship, Internal Medicine, 1970 - 1971
- University of California San Francisco School of MedicineClass of 1970
Certifications & Licensure
CA State Medical License 1971 - Present
AL State Medical License 1989 - 2023- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1983
Clinical Trials
- Antiproteinuric Agents and Fabry Disease Start of enrollment: 2001 Jan 01
- The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study Start of enrollment: 2007 Mar 01
- Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease Start of enrollment: 2011 Feb 02
Publications & Presentations
PubMed
- Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study.Katharine L Cheung, Deidra C Crews, Mary Cushman, Ya Yuan, Katherine Wilkinson, D Leann Long, Suzanne E Judd, Michael G Shlipak, Joachim H Ix, Alexander L Bullen, Davi...> ;American Journal of Kidney Diseases. 2023 Jan 6
- Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study.Christoph Wanner, Virginia Kimonis, Juan Politei, David G Warnock, Nurcan Üçeyler, Aline Frey, Peter Cornelisse, Derralyn Hughes> ;Molecular Genetics and Metabolism Reports. 2022 Jun 1
- A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm.John L Jefferies, Alison K Spencer, Heather A Lau, Matthew W Nelson, Joseph D Giuliano, Joseph W Zabinski, Costas Boussios, Gary Curhan, Richard E Gliklich, David G Wa...> ;Orphanet Journal of Rare Diseases. 2021 Dec 20
- Join now to see all
Press Mentions
Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 16th Annual WORLDSymposium(TM) 2020March 5th, 2020
Simple Test Detects Increased Risks in Patients with Acute Kidney InjuryJanuary 30th, 2015
Large Waist Doubles Risk of Kidney Disease Mortality, Study FindsJuly 15th, 2011- Join now to see all
Grant Support
- Activated Sodium Channels In HypertensionNational Institute Of Diabetes And Digestive And Kidney Diseases1997–2000
- Na+ Reabsorption And H+ Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
- Conference--Epithelial Sodium Channel Gene SuperfamilyNational Institute Of Diabetes And Digestive And Kidney Diseases1994
- Na/Ion Reabsorption And H/Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1988–1994
- General Medicine B Study SectionCenter For Scientific Review1989–1991
- Mechanisms And Consequences Of Renal HypertensionNational Institute Of Diabetes And Digestive And Kidney Diseases1988–1991
- Na/Ion Reabsorption &H/Ion Secretion Renal MechanismsNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1988
- Satellite On Membrane Transport ProteinsNational Institute Of Diabetes And Digestive And Kidney Diseases1987
- Na/Ion Reabsorption &H/Ion Secretion Renal MechanismsNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Hospital Affiliations
University of Alabama HospitalBirmingham, Alabama
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
